This trial will test the safety and effectiveness of lasmiditan in treating migraines in children aged 6-17. Up to 4 visits over 20 weeks may be required.
1 Primary · 12 Secondary · Reporting Duration: 48 Hours Postdose
Experimental Treatment
Non-Treatment Group
1633 Total Participants · 4 Treatment Groups
Primary Treatment: Lasmiditan · Has Placebo Group · Phase 3
Age 6 - 17 · All Participants · 6 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:North Carolina | 16.7% |
Louisiana | 16.7% |
Arizona | 16.7% |
Other | 50.0% |
18 - 65 | 100.0% |
Jackson Memorial Hospital | 25.0% |
Children's Hospital of New Orleans LCMC Health | 25.0% |
Long Beach Memorial Medical Center | 25.0% |
Other | 25.0% |
Met criteria | 57.1% |
Did not meet criteria | 42.9% |